54 results about "Peptide antigen" patented technology

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The embodiment of the invention provides a polypeptide antigen as well as a preparation method and application thereof. The amino acid sequence of the polypeptide antigen is Ser-Thr-Trp-Tyr-Lys-Arg, and the amino acid sequence of the polypeptide antigen is as shown in the specification. The polypeptide antigen has high conformational stability, by arranging a diphenyl cyclooctyne group (DBCO) on a side chain of a Lys residue in the polypeptide antigen and through group modification, the activity of carrying out a click chemical reaction with an endogenous or exogenous azide of a biological system is provided, and the circulation half-life period of polypeptide in a body is remarkably prolonged; through an annular structure and group modification, the polypeptide antigen can effectively target and act on T cells, and the treatment efficiency is improved.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

The invention belongs to the technical field of medicines, and particularly relates to a milk acylation modified Myh6 protein and application thereof. The antigen polypeptide for identifying the heart failure marker has an amino acid sequence as shown in SEQ ID NO: 1, lysine located at the 9th site is subjected to milk acylation modification, and the heart failure marker is milk acylation modified Myh6 protein; the milk acylation modified Myh6 protein is a lysine milk acylation modified protein (Myh6-K1897) which is located at the 1897 site of a wild type Myh6 protein. The Myh6-K1897 can be used as a marker for identifying heart failure as a target spot, is a set of novel and perfect protein milk acylation molecular regulation and control system, can judge the interaction between Myh6 and Tin, and is used for treating the core and key of heart failure. The research provides a new and powerful treatment strategy for the treatment of human heart failure diseases.

The embodiment of the present application provides a kind of polypeptide antigen and its preparation method and application.The amino acid sequence of the polypeptide antigen is Ser-Thr-Trp-Tyr-Lys-Arg.The polypeptide antigen in the present application has strong conformational stability, by setting up diphenyl cyclooctyne group (DBCO) on the side chain of Lys residue in polypeptide antigen, by group modification, provide the activity of click chemistry reaction with endogenous or exogenous azide compound in biological system, significantly prolong the circulating half-life of polypeptide in vivo;Through cyclic structure and group modification, the polypeptide antigen can effectively target and act on T cell, improve treatment efficiency.

Engineered filamentous bacteriophage particle are provided, and DNA extracted from such phage particles, including: (a) a filamentous bacteriophage capsid comprising a peptide antigen displayed on a surface of the capsid; and (b) a single stranded DNA molecule (ssDNA) encapsulated within the capsid, wherein the single stranded DNA molecule; wherein (i) the ssDNA comprises at least 12% unmethylated CG dinucleotides; (ii) the ssDNA comprises sequences encoding bacteriophage (A) fl-ori, (B) fl-term, and (C) packaging signal; and (iii) the ssDNA comprises less than 50% bacteriophage ssDNA.

The invention relates to the technical field of biological medicines, and provides an EGFR L858R mutation specific long peptide vaccine and application thereof. The long peptide vaccine provided by the invention comprises dendritic cells which are loaded by a long peptide antigen modified by a cell penetrating peptide and are induced to be mature. According to the invention, a long peptide sequence with good immunogenicity and affinity is screened out, and specific T cell immune response can be effectively induced. And the long peptide antigen is modified by adopting cell penetrating peptide (CPPs), so that efficient loading and delivery of the long peptide antigen in dendritic cells (DC) are realized. According to the vaccine, the presentation capacity of antigens is remarkably enhanced, CD8 + T cells can be effectively activated, the expression level of IFN-gamma is remarkably improved, and strong specific immune response is induced. In addition, when the vaccine is used in combination with a PD-1 antibody, the tumor immune microenvironment is further improved, and the immune activation effect is enhanced.

To provide antigen-binding proteins (ABPs) for use to discover and identify tumor-associated HLA-peptide complexes with highly positive predictive value, and for use in TCR-based immunotherapies targeting such complexes.SOLUTION: The disclosure provides an ABP that binds specifically to an HLA-peptide antigen comprising an HLA-restricted peptide forming a complex with an HLA Class I molecule, where the HLA-restricted peptide is located in the peptide binding groove of an α1 / α2 heterodimer portion of the HLA Class I molecule, where the HLA Class I molecule and the HLA-restricted peptide each have a specific amino acid sequence, and where the ABP comprises a T cell receptor (TCR) or antigen-binding fragment thereof.SELECTED DRAWING: Figure 12

A method for enhancing the immunogenicity of a protein / peptide antigen is provided, wherein the protein / peptide antigen forms a fusion protein with an Fc fragment, preferably with receptor-binding / complement-binding enhanced Fc fragment, and further forms a fusion protein glycoconjugate with a glycosyl group. In the preferred embodiment, the Fc fragment, due to alterations in its amino acid sequence and / or glycosylation, has an enhanced binding capacity to Fc receptors and / or complement protein C1q compared to its native form. Such vaccines can maintain long-term humoral and cellular immune responses, exhibiting higher cellular immune responses and producing higher titers of neutralizing antibodies in immunized animals. Using the SARS-CoV-2 RBD region as the antigen in an immunizing composition, it is formed into a fusion protein with an Fc region that has undergone amino acid sequence and fucose alteration, and further forms a fusion protein glycoconjugate with pneumococcal polysaccharide, for the prevention of SARS-CoV-2 infection-related diseases.

It has been established that the efficacy of mRNA vaccines encoding one or more peptide antigens for expression in a host cell can be enhanced by the addition of one or more mRNA sequences encoding peptide adjuvant(s) for expression of the adjuvant in the same host cell. Compositions of vaccines including mRNA sequences encoding peptide antigen(s) and peptide adjuvant(s) are described. The peptide antigen(s) and peptide adjuvant(s) can be encoded on the same or different mRNA molecule. In some forms, the vaccines include a single mRNA molecule encoding an antigen and an adjuvant, for expression in the same host cell. Nanoparticles encapsulating the mRNA sequences encoding peptide antigen(s) and peptide adjuvant(s) are provided for administration to a subject in vivo. Methods of vaccinating a subject including administering to the subject a composition including mRNA sequences encoding peptide antigen(s) and peptide adjuvant(s) are also described.

The present disclosure provides a broad-spectrum peptide antigen of SARS-COV-2, a specific neutralizing antibody and use thereof. A broad-spectrum peptide antigen of SARS-COV-2, with an amino acid sequence comprising SEQ ID NO: 1, reacts with human SARS-COV-2 positive serum, and can specifically bind to a novel coronavirus antibody. Based on the peptide sequence of the present disclosure, a fusion protein with broad-spectrum triple tandem peptides of SARS-COV-2 is prepared using PCR, prokaryotic expression, and protein purification technology which simulates the trimeric mode of SARS-COV-2 S protein in its natural state. The fusion protein is used as an antigen to immunize mice, and can produce a specific anti-SARS-CoV-2 neutralizing antibody. The neutralizing antibody may be promising in anti-infective treatment, vaccine development and detection kit development for SARS-COV-2.

Disclosed herein are methods, systems, computer-implemented methods, and computer-accessible media for modifying and / or redesigning peptide-centric chimeric antigen receptors (PC-CARs) against novel peptide antigens.

The application belongs to the technical field of biotechnology, and particularly discloses a synthetic peptide antigen of porcine circovirus type 2 Cap protein, a polyclonal antibody and application thereof. In order to solve the technical defects of low specificity and inaccurate detection of the amino acid sequence of the synthetic peptide antigen in the prior art, the application provides a synthetic peptide antigen of PCV2 Cap protein, a polyclonal antibody and application thereof. The application obtains an amino acid sequence of an antigen peptide by performing antigen peptide prediction on PCV2 Cap protein, and the applicant synthesizes the antigen peptide by using an Fmoc solid phase method, and immunizes a New Zealand white rabbit with the obtained antigen peptide to prepare a polyclonal antibody of Cap protein, the antibody can effectively react with a transiently expressed Cap protein and a Cap protein in PCV2b-infected PK15 cells, and provides a powerful tool for detection and biological function research of the PCV2 Cap protein.

An antigen-loaded nanogel is formed by loading or encapsulating one or more long peptide antigens or one or more protein antigens in a hydrophobized polysaccharide. The long peptide antigen(s) or protein antigen(s) contains (or each contain) one or more CD8+ cytotoxic T cell recognition epitopes and / or one or more CD4+ helper T cell recognition epitopes, which is / are derived from the antigen. The antigen-loaded nanogel is administered at least one day prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An immune-enhancing agent also may be administered in or with the antigen-loaded nanogel.

An immunotherapeutic composition comprising a subject-derived peripheral blood mononuclear cell (PBMC) and at least one recombinant adenoviral subtype 5 (Ad5) comprising a deletion in the E1 gene region, a deletion in the E2b gene region and a nucleic acid sequence encoding a peptide antigen wherein the PBMC is exposed ex vivo to the at least one Ad5 vector is contemplated. Advantageously, the same PBMC composition can also be used to prepare modified NK cells, and in particular the modified NKs include CIML NK cells, CENK cells and mCENK cells.

The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is unknown. Novel tumor-specific antigens (TSAs) shared by a large proportion of ovarian tumors are described herein. Most of the TSAs (>80%) described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also described.

The invention provides a monoclonal antibody of a humanized anti-ATR001 oligopeptide antigen, an antibody quantitative detection kit and application. The monoclonal antibody comprises a heavy chain and a light chain of a specific amino acid sequence, and the kit comprises a coated plate coated with an ATR001 oligopeptide antigen, a standard substance, a matched diluent, a horse radish peroxidase labeled goat anti-human IgG antibody, a developing solution, a stop solution and a concentrated washing solution. The ATR001 oligopeptide antigen is moderately modified, so that the ATR001 oligopeptide antigen has higher coating stability and easiness in coupling, and the sensitivity and the specificity of a detection method can be remarkably improved. The kit disclosed by the invention can be used for detecting the level of the anti-ATR001 oligopeptide antibody generated in human serum after subcutaneous injection of the ATRQbeta-001 therapeutic antihypertensive vaccine, so that an immune response and immunogenicity evaluation method is provided for clinical application of the vaccine.

To provide a technique for more surely achieving a higher viable cell rate while adopting a transposon method for CAR gene transfer in preparation of CAR-T cells.SOLUTION: Disclosed is a method for preparing a genetically modified T cell that expresses a chimeric antigen receptor, which comprises the following steps (i) to (iv): (i) a step of culturing the genetically modified T cell in a monocyte-depleted T cell-containing cell population; A step of preparing non-proliferative cells holding a viral peptide antigen, which are obtained by performing a culture treatment in the presence of a viral peptide antigen and a treatment for losing proliferation ability; (ii) a step of obtaining genetically modified T cells in which a target antigen-specific chimeric antigen receptor gene is introduced by a transposon method from a T cell-containing cell population subjected to a monocyte-reducing treatment; (iii) a step of mixing and co-culturing the non-proliferative cells prepared in step (i) and the genetically modified T cells obtained in step (ii); and (iv) a step of collecting cells after culture.SELECTED DRAWING: None

The application relates to the field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD8 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD8 polypeptide antigen, a New Zealand white rabbit is immunized by adopting a KLH coupled CD8 antigen polypeptide combined with a rapid immunoadjuvant, high-affinity antibody clones are obtained by single B cell sorting technology, and the antibody is prepared by recombination expression. The antibody is verified by ELISA and flow cytometry, has high titer and strong specificity, can effectively recognize human peripheral blood CD8+ T cells, and has a signal strength and a background signal-to-noise ratio which are significantly better than those of a traditional mouse-derived antibody. The application provides light and heavy chain variable region amino acid sequences of the antibody, realizes controllable preparation of the antibody and protection of intellectual property rights. The antibody can be widely applied to the fields of flow cytometry detection, immunohistochemistry, tumor immunotherapy monitoring and T cell function research, and has important scientific research and clinical application values.

The invention relates to the field of biological medicine and immunotherapy, and particularly provides a liver cancer neoantigen vaccine based on immunopeptidomics and immunotherapy application of the liver cancer neoantigen vaccine. According to the invention, an MHC-I immunoprecipitation technology is combined with high-throughput mass spectrometry, a neoantigen short peptide group with excellent immunogenicity is identified from a liver cancer sample, and a long peptide group is obtained by extension on the basis of short peptides. The oligopeptide antigen and the long peptide antigen are respectively mixed with an adjuvant Poly (I: C) to prepare a vaccine, and a mouse liver cancer model proves that the vaccine can effectively inhibit tumor progression and induce a tumor microenvironment to be converted into an immune activation state. The invention provides a new antigen source and a vaccine form for individualized liver cancer immunotherapy, and has remarkable clinical application potential and industrialization prospect.

This invention relates to the field of biotechnology and provides an antigenic epitope of the parainfluenza virus type 5 F protein, a monoclonal antibody, and its applications. 135 AAILNLKNAIQKTNAAVADVVQA 157 Furthermore, a monoclonal antibody that specifically recognizes this antigenic epitope is provided. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The discovery of this epitope provides a new target for the development of PIV5 diagnostic reagents. Peptide antigens can be designed and synthesized based on this epitope to develop highly specific ELISA diagnostic kits. Simultaneously, this epitope can be used as a candidate epitope for the design of multi-epitope vaccines, providing a new strategy for the prevention and control of PIV5.

The present invention relates to a vaccine composition. A vaccine composition according to the present invention comprises a nucleic acid and an adjuvant, wherein the nucleic acid comprises mRNA encoding a peptide antigen. The vaccine composition has an enhanced capability of specifically producing an antibody against the peptide antigen and / or an enhanced capability of inducing antigen-specific cellular immunity against the peptide antigen compared with a control composition that does not contain an adjuvant. In a preferred aspect, the adjuvant includes (i) an adjuvant comprising a mineral acid salt, (ii) an inflammatory cytokine inducer, or, more preferably, (iii) a combination of an inflammatory cytokine inducer and an adjuvant comprising a mineral acid salt.

A method for enhancing the immunogenicity of a protein / peptide antigen, wherein the protein / peptide antigen forms a fusion protein with an engineered antibody Fc fragment, which has an altered amino acid sequence and / or glycosylation form, and has an improved binding ability to Fc receptors and / or complement protein C1q compared with its native form. The SARS-CoV-2 vaccine prepared with the fusion protein as an immunogen has a higher binding ability to Fc receptors, can maintain long-term humoral and cellular immune responses, and the immunized animals can produce higher titers of neutralizing antibodies. The recombinant protein vaccine can be used for preventing SARS-CoV-2 infection-related diseases.

The application relates to the technical field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD4 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD4 polypeptide antigen. The antibody has high affinity and good specificity, and can effectively recognize CD4 positive T cells in human peripheral blood. The antibody is verified by ELISA and flow cytometry, and has high titer, low background and a signal-to-noise ratio superior to that of existing mouse-derived antibodies. Further, the amino acid sequences of the light chain and the heavy chain variable region of the antibody are obtained, so that controllability and repeatability of antibody expression are realized. The antibody can be widely applied to scenes such as immunodetection, HIV auxiliary diagnosis, T cell subgroup research and antibody engineering development, and has important scientific research and industrial values.